ECOG OPERATIONS OFFICE

ECOG 运营办公室

• 批准号: 3556596
• 负责人: DOUGLASS C TORMEY
• 金额: $ 159.71万
• 依托单位: AMC CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-09-01 至 1994-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3556596
• 关键词: DNA replication; Epstein Barr virus; acute leukemia; breast neoplasm /cancer diagnosis; breast neoplasms; cancer information system; carmustine; combination cancer therapy; combination chemotherapy; computer assisted diagnosis; cooperative study; cytogenetics; drug adverse effect; endocrine neoplasm; epidermal growth factor; estrogen receptors; flow cytometry; gene expression; head /neck neoplasm; histopathology; human subject; human therapy evaluation; immunocytochemistry; in situ hybridization; kidney neoplasms; lung neoplasms; lymphadenectomy; melanoma; metastasis; myelogenous leukemia; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplasm /cancer genetics; neoplasm /cancer immunodiagnosis; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer thermotherapy; oncogenes; prognosis; radiation therapy dosage; surface antigens

The overall goal of the ECOG Operations Office is to provide leadership and support for multi disciplinary clinical trials designed to improve cancer therapy. To achieve this the specific aims are as follows: A. Improving clinical trials efficiency by diminishing lag times in protocol development, forms development, and protocol review; developing (computer) on-line randomization access and checklists; and eliminating unnecessary requirements for registration, on study requirements and follow up measurements. B. Initiating new scientific thrusts by incorporating into our clinical trials elements of modern cancer biology, including biologic response modifier agents, growth factors, immunochemistry, molecular probes for oncogenes, and cytogenetics. C. Providing resources to our MOC and DOC chairs to support protocol development, to initiate implementation of laboratory projects, to monitor the conduct of trials, and to plan for new studies. D. Enhancing the accrual of patients into major protocols such as the NCI high priority initiatives, Phase 3 trials and Genitourinary cancers by providing administrative and fiscal support to enlist patients from new or established participants.

西非经济共同体行动办公室的总体目标是提供